Preoperative bisphosphonates were linked to fewer postoperative neurocognitive events in osteoporosis
Postoperative neurocognitive complications remain among the most disruptive problems in older surgical patients, especially when they prolong recovery, complicate discharge planning, and drive extra utilization after an operation. In a nationwide propensity score–matched cohort study using TriNetX data, bisphosphonate therapy given before surgery was associated with substantially lower recorded rates of delirium and several related neurocognitive outcomes in adults with osteoporosis.
The study drew on U.S. adults with osteoporosis who underwent surgery between 2005 and 2025. Exposure was defined by prescriptions recorded within 90 days before surgery, with a 365-day window used for zoledronic acid. After matching, the analysis included 228,662 pairs, creating one of the largest real-world datasets yet used to examine whether a bone-targeted therapy might also track with postoperative brain outcomes.
Delirium, antipsychotic use, and delayed recovery diverged sharply
The primary endpoint was delirium within 30 days after surgery, and the separation between groups was large. Preoperative bisphosphonate use was associated with a relative risk of 0.38 for delirium, with a 95% confidence interval of 0.30 to 0.48. In practical terms, the coded diagnosis of delirium appeared far less often in the exposed cohort than in matched controls.
Secondary outcomes moved in the same direction. Antipsychotic initiation carried a relative risk of 0.40, with a 95% confidence interval of 0.36 to 0.43. Delayed neurocognitive recovery was also lower, with a relative risk of 0.76 and a 95% confidence interval of 0.66 to 0.86. Psychotic or behavioral syndromes were less frequent as well, with a relative risk of 0.60 and a 95% confidence interval of 0.45 to 0.81. All of these findings were statistically robust, with p values below 0.0001 for the first three outcomes and 0.0006 for psychotic or behavioral syndromes.
The pattern matters because these outcomes do not represent isolated chart abstractions. Delirium often triggers antipsychotic treatment, extended monitoring, delayed mobilization, and a more complicated discharge trajectory. Delayed neurocognitive recovery can slow rehabilitation long after anesthesia has worn off, particularly in older adults who already carry a heavier physiologic burden from osteoporosis and frailty-related comorbidity.
A medication aimed at bone may be influencing inflammation and perioperative vulnerability
Bisphosphonates are prescribed to suppress bone resorption, but their biologic reach may extend beyond the skeleton. The perioperative period is marked by systemic stress, inflammatory activation, sleep disruption, pain, opioid exposure, and hemodynamic fluctuation, all of which can destabilize cognitive function in vulnerable patients. A drug that alters osteoclast activity may also intersect with inflammatory signaling pathways that matter to the brain, or simply identify patients whose chronic disease is being managed more consistently before surgery.
That biological plausibility does not prove causality. Even so, the magnitude of the association invites attention because the signal appeared not only in delirium but also in neurocognitive recovery, behavioral syndromes, and downstream utilization outcomes. Preoperative treatment may mark better medical optimization, more stable outpatient follow-up, or a lower burden of unmeasured risk factors that also shape postoperative cognition.
Lower utilization followed the neurocognitive signal
The analysis extended beyond neurological endpoints. Bisphosphonate use was associated with lower risks of intensive care unit admission, emergency department visits, and hospital readmission. Those findings fit a broader perioperative profile in which fewer cognitive complications can translate into fewer escalations of care and less postdischarge instability.
Even a modest reduction in delirium can ripple outward quickly. A patient who does not become agitated, disoriented, or difficult to redirect is less likely to need sedating rescue medication, intensive observation, or transfer to a higher level of care. The cascade is familiar to anesthesiologists, surgeons, and ward teams: once postoperative confusion begins, resource use rises fast.
Residual confounding remains the central caution
The design was retrospective, observational, and based on administrative data from a large electronic health record network. Propensity score matching improves balance, but it cannot remove confounding by indication, differences in baseline frailty, medication adherence, surgical complexity, anesthesia technique, or the reasons one patient receives osteoporosis treatment while another does not. Under-ascertainment of outcomes is also a real concern, especially for delirium and delayed neurocognitive recovery, which are frequently missed unless someone is actively looking for them.
The cohort included adults with osteoporosis undergoing surgery across the United States over a 20-year span, but the study does not establish that bisphosphonates directly prevent postoperative brain dysfunction. It shows an association, not a proven perioperative neuroprotective effect. The data also do not reveal which operations carried the greatest risk, how anesthetic management differed, or whether timing and duration of bisphosphonate exposure mattered within the 90-day window.
Still, the findings are difficult to ignore because the direction of effect was consistent across several clinically meaningful outcomes. If the association survives prospective testing, preoperative osteoporosis management could carry implications beyond fracture prevention. It may become part of a broader conversation about surgical optimization and cognitive safety in older adults.
What this could mean at the bedside
For clinicians caring for older surgical patients with osteoporosis, the study suggests one more reason to think carefully about medication history before an operation. Preoperative bisphosphonate exposure may identify patients who are already engaged in longitudinal care, but it may also reflect a biologic state less prone to postoperative cognitive disruption. Either way, the signal supports closer scrutiny of how chronic bone therapy intersects with delirium prevention strategies, especially in patients already at risk for prolonged recovery.
The work leaves several questions unanswered: whether the association holds across specific procedures, whether the effect differs by agent, and whether the apparent benefit is driven by pharmacology, confounding, or both. Those answers will require prospective studies with direct delirium ascertainment, surgical detail, and tighter control of perioperative variables.